With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.
The bromodomain market has exploded in recent years with many more agents in the development. Are they all the same though?
Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas?
We asked experts at AACR what they really thought...
A look at Bayer's early oncology pipeline and a curious new class called MNK (Mink) inhibitors
What can we learn about clinical trial design from immunotherapy combinations?
How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!
A look at small biotechs producing quality preclinical data at #AACR16 that may lead to clinical development in the near future
A look at the BCMA/APRIL landscape in multiple myeloma - this is rapidly becoming a competitive target
Beyond checkpoint blockade, companies are now exploring what happens when you combine them with immune agonists such as OX40. Here we explore an industry perspective.
A wide ranging discussion about how to light the fires in non-immunogenic or cold tumours - OX40, STING, vaccines and more discussed!
At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.
Can we safely and effectively add a checkpoint inhibitor to standard chemotherapy and VEGF inhibition?
Early proof of concept in patients with metastatic colorectal cancer.
Chemotherapy can have a potentiating effect on cancer immunotherapy. The positive effects may surprise some readers...
What were the major learning points from AACR that will make an impact over the next 1-2 years? Chhhhanges are afoot...
Season 2 of the Novel Targets has launched, plus the eagerly awaited April Readers Q&A Mailbag
Commentary on Tuesday sessions at AACR 2016 annual meeting
Commentary on Monday at AACR 2016 annual meeting
Commentary from Sunday at 2016 AACR annual meeting
Commentary on Day 1 of AACR 2016 annual meeting in New Orleans.
Where next for Bcl2 inhibitors beyond CLL and Del17p? Which novel combinations might be an attractive strategy?
In this preview of AACR 2016, we're looking at the CD40 landscape, some of the new companies that have entered the scene and what presentations to look out for at AACR 2016 (and why they matter).
Today post is on OX40 (CD134) as a novel immuno-target and what the OX40 cancer immunotherapy landscape looks like.
There are now several agonist antibodies in development and entering the clinic that seek to activate GITR, and new data is expected at AACR 2016.
This post looks at some of the data at AACR 2016 for cancer immunotherapies that target IDO1 and TDO and their downstream effectors.
The discovery of a novel target in castration-resistant prostate cancer offers the potential to overcome or delay acquired resistance to enzalutamide.
A look at alternative checkpoint inhibitors, anti-TIM-3 and LAG-3 compounds in early development at AACR
In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.
Commentary on some of the latest cancer immunotherapy papers
Subscriber questions on recent immuno-oncology, Genentech, Kite Pharma and Gilead company news
Pick of 10 abstracts at AACR 2016 annual meeting in New Orleans that may answer critical cancer research questions
Cancer Immunotherapy dominates AACR 2016 annual meeting in New Orleans.
Finding new ways to optimise CAR T cell therapy in CLL and solid tumours may be closer than you think...